(MedPage Today) — CHICAGO — Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received a PARP inhibitor in addition…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115861
Author :
Publish date : 2025-06-03 12:00:00
Copyright for syndicated content belongs to the linked Source.
